RHJA
ALBO

Rice Hall James & Associates’s Albireo Pharma Inc ALBO Stock Holding History

Rice Hall James & Associates’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-513,525
Closed -$11.1M – 274
2022
Q4 		$11.1M Buy
513,525
+9,387
+2% +$198K 0.64% 46
2022
Q3 		$9.76M Buy
504,138
+38,334
+8% +$793K 0.57% 48
2022
Q2 		$9.25M Sell
465,804
-9,187
-2% -$242K 0.45% 59
2022
Q1 		$14.2M Buy
474,991
+16,980
+4% +$497K 0.56% 53
2021
Q4 		$10.7M Sell
458,011
-49,670
-10% -$1.32M 0.38% 65
2021
Q3 		$15.8M Sell
507,681
-2,786
-0.5% -$86.2K 0.59% 53
2021
Q2 		$18M Sell
510,467
-62,432
-11% -$2.03M 0.64% 52
2021
Q1 		$20.2M Buy
572,899
+315,527
+123% +$11.6M 0.66% 47
2020
Q4 		$9.65M Buy
257,372
+170,014
+195% +$6.18M 0.34% 64
2020
Q3 		$2.92M Buy
+87,358
New +$2.54M 0.12% 130

Other funds holding ALBO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Rice Hall James & Associates's ALBO Position: Q1 2023 in Review

Rice Hall James & Associates sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 513,525 shares — an estimated $11.1M sold.

Rice Hall James & Associates first reported a position in ALBO in Q3 2020 and held it in 10 quarters. The position peaked at $20.2M in Q1 2021. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

  • Rice Hall James & Associates reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
  • Rice Hall James & Associates sold 513,525 Albireo Pharma Inc shares in Q1 2023, an estimated $11.1M.
  • Rice Hall James & Associates first reported a position in Albireo Pharma Inc in Q3 2020 and held it in 10 quarters.
  • Rice Hall James & Associates's Albireo Pharma Inc position peaked at $20.2M in Q1 2021.
  • 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Rice Hall James & Associates's 13F filing for Q1 2023, filed 12 May 2023.